Brother Enterprises (002562)2023-10-30 16:00Financial Performance - The company's revenue for Q3 2023 was ¥690,514,551.08, representing a decrease of 18.04% compared to the same period last year[6]. - The net profit attributable to shareholders was a loss of ¥42,301,782.91, a decline of 196.61% year-on-year[6]. - The basic earnings per share were -¥0.037, down 192.50% from the same period last year[6]. - Total revenue for the third quarter of 2023 was CNY 2,158,144,636.62, a decrease of 18.6% compared to CNY 2,651,745,529.19 in the same period last year[24]. - The total revenue for the third quarter was approximately CNY 18.66 million, a significant decrease compared to CNY 351.80 million in the same period last year, reflecting a decline of about 94.7%[25]. - The net profit for the third quarter was CNY 2.64 million, down from CNY 274.42 million year-over-year, indicating a decline of approximately 99.0%[25]. - The company reported a total comprehensive income of CNY -49.08 million for the third quarter, compared to CNY 352.23 million in the same quarter last year, reflecting a decline of about 113.9%[25]. - Basic and diluted earnings per share for the third quarter were CNY 0.003, a significant drop from CNY 0.26 in the previous year[25]. Cash Flow and Liquidity - The net cash flow from operating activities was negative at ¥73,879,866.00, a decrease of 137.57% compared to the previous year[12]. - The cash flow from operating activities showed a net outflow of CNY 73.88 million, contrasting with a net inflow of CNY 196.65 million in the previous year, representing a change of about 137.5%[26]. - The cash and cash equivalents decreased to CNY 218,662,680.04 from CNY 327,111,533.88, representing a decline of 33.2%[21]. - The cash and cash equivalents at the end of the period were CNY 190.57 million, down from CNY 709.43 million at the end of the previous year, a decrease of approximately 73.1%[27]. - The cash inflow from investment activities was CNY 625.89 million, a decrease from CNY 1.52 billion in the same period last year, indicating a decline of approximately 58.9%[26]. - The net cash flow from financing activities was CNY 107.71 million, compared to a net outflow of CNY 74.96 million in the previous year, showing a turnaround[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,804,856,055.53, an increase of 1.85% from the end of the previous year[6]. - Total liabilities increased to CNY 2,585,569,571.99 from CNY 2,326,094,438.77, marking a rise of 11.1%[21]. - Non-current assets totaled CNY 4,017,373,070.86, up from CNY 3,632,958,702.18, indicating an increase of 10.6%[21]. - Total assets reached CNY 5,804,856,055.53, compared to CNY 5,699,257,406.29, reflecting a growth of 1.8%[21]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 49,385[13]. - The largest shareholder, Qian Zhida, holds 24.22% of shares, totaling 257,395,438 shares, with 90 million shares pledged[13]. - The second-largest shareholder, Qian Zhiming, holds 20.15% of shares, totaling 214,182,400 shares, with 30 million shares pledged[13]. - The top 10 shareholders hold a significant portion of the company's shares, with the first two shareholders alone accounting for over 44%[13]. - The company has a total of 64,348,860 unrestricted shares held by Qian Zhida[14]. - The company has a total of 0 preferred shareholders at the end of the reporting period[15]. Investment and Future Plans - The company plans to invest a total of 2.5 billion RMB in the construction of an international pharmaceutical industry base, with 1.5 billion RMB allocated for fixed assets and 1 billion RMB for R&D[15]. - The company aims to raise up to 800 million RMB through a private placement to fund the construction of a 1,150-ton iodine contrast agent raw material project and to supplement working capital[16]. - The company is in the process of obtaining land for the pharmaceutical project, which involves certain uncertainties regarding timing and area[15]. Borrowings and Financing - The company experienced a 63.85% increase in short-term loans, totaling ¥756,572,037.50, due to increased working capital needs[10]. - The company received CNY 915 million in borrowings during the financing activities, an increase from CNY 560 million in the previous year, reflecting a growth of approximately 63.6%[27].